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Arginine vasopressin and 
Copeptin in Perinatology
Katrina Suzanne Evers and Sven Wellmann*
Division of Neonatology, University of Basel Children’s Hospital (UKBB), Basel, Switzerland
Arginine vasopressin (AVP) plays a major role in the homeostasis of fluid balance,
vascular tonus, and the regulation of the endocrine stress response. The measurement 
of AVP levels is difficult due to its short half-life and laborious method of detection. 
Copeptin is a more stable peptide derived from the same precursor molecule, is
released in an equimolar ratio to AVP, and has a very similar response to osmotic, 
hemodynamic, and stress-related stimuli. In fact, copeptin has been propagated as 
surrogate marker to indirectly determine circulating AVP concentrations in various con-
ditions. Here, we present an overview of the current knowledge on AVP and copeptin 
in perinatology with a particular focus on the baby’s transition from placenta to lung 
breathing. We performed a systematic review of the literature on fetal stress hormone 
levels, including norepinephrine, cortisol, AVP, and copeptin, in regard to birth stress. 
Finally, diagnostic and therapeutic options for copeptin measurement and AVP func-
tions are discussed.
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iNTRODUCTiON
The nature of stress hormones is comparable to that of firefighters: they act fast on demand and pull 
back as soon as possible. While firefighters return to the firehouse for recreation once their task is 
finished, the activity of stress hormones is naturally limited due to their short half-life, which allows 
for a targeted and time-limited action but complicates their detection in the circulatory system. One 
such stress hormone is arginine vasopressin (AVP), also known as antidiuretic hormone (ADH), 
which is a small peptide with a multitude of functions in many systems, including the central nervous 
system (CNS). Fortunately, AVP is derived together with three other peptides from a larger precursor 
peptide, and one of these peptides, copeptin, is more stable than AVP itself and is released in a 1:1 
ratio to AVP. One decade ago, a quantitative copeptin sandwich immunoassay was developed (1), 
and since then, a large variety of clinical studies demonstrated the usefulness of copeptin to indirectly 
determine circulating AVP concentrations.
This review briefly summarizes the basic information on AVP and copeptin in general, including 
their production and action via AVP receptors, followed by analysis of the relationship between 
labor and stress hormone release and the action of AVP in healthy neonates and in newborn 
diseases. The particular focus of this review is on the role of AVP in the transition from placenta 
to lung breathing and in acute and chronic stress responses. We performed a systematic review 
of the literature on various stress hormones at birth, such as norepinephrine, cortisol, AVP, and 
copeptin, and present them here. Finally, the therapeutic and diagnostic avenues of AVP and 
copeptin are outlined.
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PRODUCTiON OF AvP AND COPePTiN
Arginine vasopressin is produced as a larger precursor pre-
proAVP by magnocellular and parvocellular neurons within 
the paraventricular nucleus (PVN) and the supraoptic nucleus 
(SON) of the hypothalamus (2). Pre-proAVP is produced by 
magnocellular neurons of the PVN and SON, is packaged into 
neurosecretory granules, and is transported axonally to the 
posterior pituitary, also called the neurohypophysis. En route, 
pre-proAVP is enzymatically processed into four peptides: the 
N-terminal signal peptide, the active hormone AVP, neurophysin 
2, and the C-terminal copeptin. Upon activation with various 
stimuli, the stored peptides AVP, neurophysin 2, and copeptin 
are secreted into the circulatory system in equimolar amounts. 
The pre-proAVP produced in parvocellular neurons in the PVN 
is transported by axons projecting to the median eminence where 
it is processed and secreted into the hypothalamic–hypophysial 
portal vessels and ultimately reaches its destination, the anterior 
pituitary. A third portion is produced by parvocellular neurons 
of the PVN, the medial amygdala, the bed nucleus of the stria 
terminalis, and the suprachiasmatic nucleus, with projections 
toward distinct brain regions (3). Together, there are at least three 
distinct pathways by which AVP exerts its functions. First, AVP 
regulates water absorption via the posterior pituitary. Second, 
AVP is critically involved in the hypothalamic-pituitary-adrenal 
(HPA) stress axis via the posterior pituitary. Third, AVP remain-
ing in the CNS contributes to behavior and cognitive functions.
AvP ReCePTORS
The receptors for AVP have been divided into three major types, 
V1a, V1b (or V3), and V2, according to their pharmacological 
and G-protein-coupled properties (2). AVP released into the 
circulatory system functions as a peripheral hormone by bind-
ing to its receptors located at the plasma membrane of various 
target cells. The V1a receptor is predominantly found in vascular 
smooth muscle and is involved in the control of vasoconstrictor 
effects and blood pressure regulation. V1b receptors are primarily 
located on specialized cells, called corticotrophs, in the anterior 
pituitary gland, where they stimulate the release of adrenocor-
ticotropic hormone (ACTH) synergistically with corticotropin-
releasing hormone (CRH). The V2 receptor expressed on kidney 
cells is responsible for water reabsorption in the collecting ducts 
by activating aquaporin-2 channels, whereas its expression on 
endothelial cells of the vasculature and platelets makes AVP an 
important hormone in hemostasis. V1a and V1b receptors are 
found in the brain. Finally, AVP binds to the oxytocin receptor, 
which further increases its complexity (4).
AvP AND COPePTiN MeASUReMeNT
The measurement of AVP is cumbersome and complex due to 
several pre-analytical obstacles; thus, the detection of AVP is 
unsuited for clinical diagnostics and is limited to a few special-
ized laboratories (5). For example, 90% of AVP in the circulatory 
system is bound to platelets, which falsifies the actual amounts of 
circulating AVP (6). AVP is a bioactive peptide hormone that is 
tightly regulated and rapidly cleared from the circulation, with 
an in vivo half-life of less than 30 min (7). And to make matters 
worse, AVP is unstable in isolated plasma, even when stored at 
−20°C (8). In contrast, copeptin does not have such limitations 
(5). Several copeptin assays are currently available, but the only 
assays with sufficient technical descriptions and clinical data to 
justify their routine clinical use are the original sandwich immu-
noluminometric assay (1) and its automated immunofluorescent 
successor (on the KRYPTOR platform). In conclusion, the great 
advantages of copeptin measurement are the remarkably high 
sensitivity of this robust AVP surrogate marker, its extreme stabil-
ity once collected in blood sampling tubes, and the fact that only 
50 μl of serum or plasma are needed for the assay (9).
SURGe iN FeTAL STReSS HORMONeS
An important “side effect” of vaginal delivery is the surge in 
fetal stress hormones, including catecholamines, cortisol, and 
AVP. These stress hormones are widely recognized to facilitate 
the transition of the newborn to air breathing, cardiovascular 
adaptation, thermogenesis, glucose, and water homeostasis. It 
has been four decades since the first results on AVP concentra-
tions in an infant’s umbilical cord blood at birth were published, 
which indicated strongly elevated AVP concentrations (10–16). 
These initial studies have led to the following key findings: (1) 
cord blood AVP is of fetal origin because AVP concentrations in 
arterial cord blood are higher than values reported in venous cord 
blood (arteriovenous gradient) and because AVP is absent in cord 
blood of anencephalic infants (10–12, 14, 16, 17), (2) cord blood 
AVP levels in infants delivered vaginally are much higher than 
those in infants delivered by cesarean section performed before 
the onset of labor (15, 16), (3) cord blood AVP levels correlate 
positively with fetal distress measured as cord blood pH (17) and 
have been reported to be exceedingly high in asphyxiated infants 
(10, 14, 18), leading to the assumption of “pituitary exhaustion” 
(10), and (4) following delivery, AVP levels drop rapidly within a 
few hours to adult basal levels (16, 19).
With the goal to study systematically the surge of AVP and 
copeptin levels at birth in comparison to other stress hormones, 
namely cortisol and norepinephrine, we performed a systematic 
review of the literature. The authors independently searched 
the database Medline, available via PubMed, retrieved, and 
reviewed studies for eligibility and extracted data. All disagree-
ments encountered in the review process were resolved through 
consensus. We included studies that met the following criteria: 
(1) study design: cohort, cross-sectional, or case-control studies 
in humans, which evaluated the relationship between different 
delivery modes and concentrations of stress hormones in healthy 
term-born infants at birth. Only studies comparing unassisted 
vaginal delivery with primary cesarean section were included. 
Studies were excluded from this review if they reported emer-
gency or secondary cesarean sections, the latter are cesareans 
with contractions or rupture of the membranes, and if a study 
reported only data on either vaginal deliveries or primary cesar-
ean sections. (2) Outcome measures: plasma or serum concentra-
tions of cortisol, norepinephrine, AVP, and copeptin in arterial 
or venous umbilical cord blood collected at birth. (3) Statistical 
FiGURe 1 | Fold change of norepinephrine, cortisol, AvP, and copeptin between primary cesarean section and vaginal delivery. Study data were 
retrieved from the published literature and listed in chronologic order from oldest to newest on x-axis, corresponding references are given in Section “Surge in Fetal 
Stress Hormones” for all four hormones. The size of the diamonds reflects the study sample size: small corresponds to n = 0–50, middle n = 50–100, and large 
n = 100–170. Circles reflect the weighted mean values depending on sample size and are given at the final position of the x-axis.
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analysis: the authors of the studies must have presented hormone 
concentrations as medians or means as well as patient numbers 
of each delivery group separately. Searches were carried out to 
identify studies for each hormone concerned with: (1) neonate, 
(2) umbilical cord blood, and (3) delivery or birth. These three 
concepts were linked by the “AND” operator. A variety of search 
terms was used within each concept, e.g., (1) newborn, baby, 
infant, fetus; (2) cord blood, serum, plasma; and (3) parturition, 
delivery mode, birth stress. Both free text and subject headings 
(MeSH terms) were used.
For cortisol, 47 studies, norepinephrine 19, AVP 9, and for 
copeptin, 7 studies were eligible and data were retrieved. Data 
are presented in Figure 1 as fold change between vaginal delivery 
and primary cesarean section of cortisol, norepinephrine, AVP, 
and copeptin in separate panels. For each hormone, a mean fold 
change is given weighted with respect to sample size. Studies are 
numbered chronologically, and the corresponding references are 
as follows:
Cortisol: 1 (20), 2 (21), 3 (22), 4 (23), 5 (24), 6 (25), 7 (26), 8 
(27), 9 (28), 10 (29), 11 (30), 12 (31), 13 (32), 14 (33), 15 (34), 16 
(35), 17 (36), 18 (37), 19 (38), 20 (39), 21 (40), 22 (41), 23 (42), 24 
(43), 25 (44), 26 (45), 27 (46), 28 (47), 29 (48), 30 (49), 31 (50), 32 
(51), 33 (52), 34 (53), 35 (54), 36 (55), 37 (56), 38 (57), 39 (58), 40 
(59), 41 (60), 42 (61), 43 (62), 44 (63), 45 (64), 46 (65), and 47 (66); 
Norepinephrine: 1 (67), 2 (68), 3 (33), 4 (69), 5 (70), 6 (71), 7 (72), 
8 (73), 9 (74), 10 (36), 11 (75), 12 (76), 13 (77), 14 (78), 15 (79), 
16 (80), 17 (81), 18 (55), and 19 (66); and AVP: 1 (11), 2 (12), 3 
(15), 4 (16), 5 (82), 6 (83), 7 (41), 8 (84), and 9 (85). Copeptin: 1 
(86), 2 (87), 3 (88), 4 (89), 5 (90), 6 (91), and 7 (92).
In summary, all four hormones were higher in the cord blood 
of infants after vaginal delivery than after primary cesarean sec-
tion, with highest values observed for AVP (14-fold) and copep-
tin (97-fold). Of note, we identified a few studies that reported 
no difference (cortisol study number 13 and 26, copeptin study 
number 3) or lower values after vaginal delivery (norepinephrine 
study 1 and 16) (Figure 1). For the studies on cortisol and norepi-
nephrine, we could not identify a specific reason. With respect to 
copeptin, five out of seven included studies conducted copeptin 
measurements using the validated BRAHMS KRYPTOR immu-
noanalyzer (Thermo Scientific Brahms GmbH, Hennigsdorf, 
Germany). Study number 3 used the human copeptin ELISA kit 
from Cusabio Inc. (Cusabio Biotech Co., USA) and study number 
7 used the ELISA kit from Phoenix Pharmaceuticals Inc. (Phoenix 
Pharmaceuticals Inc., Karlsruhe, Germany), where both studies 
showed fold change below fivefold.
Both AVP and copeptin concentrations are significantly 
higher in infants after secondary cesarean section and assisted 
vaginal delivery as compared to primary cesarean and spontane-
ous delivery, respectively (11, 15, 16, 86, 90, 93). In addition, AVP 
and copeptin are closely related with metabolic stress markers 
pH, negative base excess, and lactate at birth, with highest 
concentrations after perinatal hypoxia ischemia, see also 
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below (86, 87, 94, 95). Together, these findings support the 
pivotal role of AVP and copeptin as fetal stress markers.
LABOR AND AvP AND COPePTiN 
ReLeASe
Birth is more than just the few minutes of delivery. It is a complex 
process that involves the preparation of the mother’s and infant’s 
bodies. Maternal labor is the driving force in vaginal delivery, 
as it encourages the mother’s body to dilate the cervix and to 
push the fetus through the birth canal (96). Normal labor is 
initiated by the removal of the inhibitory effects of pregnancy 
on the myometrium rather than an active process governed by 
uterine stimulants (97). The uterus is usually maintained in a 
state of quiescence during pregnancy. Myometrium inhibition 
occurs via the integrated action of different inhibitors, and their 
effect diminishes near term due to the activation of the uterus 
with regular uterine contractions accompanied by slow cervical 
dilation. This process represents the latent phase of the first stage 
of labor, which ultimately results in the descent of the fetal head 
into the pelvis. The second stage of labor begins when the cervix 
is fully dilated and ends with the delivery of the infant. Stage three 
events (uterine involution) occur after delivery. During the first 
and second stages of labor, each uterine contraction leads to a 
brief pO2 drop in the fetus, often without noticeable changes in 
fetal heart rate tracings (98–100). Data from animal studies show 
a direct and dose-dependent link between uterine contractions 
and fetal arterial pO2 changes (101, 102), as well as a relationship 
between arterial pO2 and plasma AVP in fetal sheep (103–105). 
Furthermore, AVP stimulates ACTH release and cortisol secre-
tion, as demonstrated repeatedly in fetal sheep (106–109). Even 
small changes in fetal arterial pO2 of 2.5 mmHg were sufficient to 
cause ACTH release, a key hormone of the HPA axis downstream 
of AVP and CRH (110). Arterial hypoxia is a strong trigger of 
AVP (111) and copeptin release (112), and brief events of a few 
minutes of hypoxia are sufficient to cause a fivefold increase in 
copeptin levels (113). Very recently, we completed a randomized 
controlled trial with a truncated oxytocin challenge test 2 h prior 
to elective cesarean section with subsequent arterial umbilical 
cord blood sampling at birth. Plasma copeptin levels were found 
to be threefold higher in the newborn babies of the oxytocin group 
than in the placebo infants without any evidence of fetal acidosis 
(114). Interestingly, only half the women in the oxytocin group 
noticed the contractions, indicating that the mild subclinical 
contractions are sufficient to trigger fetal AVP/copeptin release.
Thus, we conclude that uterine contractions precondition the 
fetus by activating the fetal HPA axis hours and days before birth. 
AVP plays a key role in this cascade. After small fetal arterial pO2 
changes due to uterine contractions, fetal AVP is released with 
subsequent ACTH and cortisol secretion.
AvP iN HeALTHY NeONATeS
Arginine vasopressin is related to a variety of transitional pro-
cesses at birth, including water homeostasis, breathing, peripheral 
analgesia, regulation of the vasculature resistance, and platelet 
function, which are summarized below and shown in Figure 2.
Body Fluid Homeostasis
Increased AVP levels at birth have been linked to delayed first 
voiding in newborns (93, 115), and copeptin concentrations at 
birth are inversely related to postnatal weight loss by day 3 of 
life (86). Reducing urinary water loss at birth until the enteral 
supply picks with the establishment of lactation appears to be 
a prudent strategy, and cesarean section without any previous 
labor deprives the newborn infant of the wave of fetal AVP, which 
serves as a preemptive adaptation. In fact, the extent of weight loss 
is much greater in newborns born by cesarean than by vaginal 
delivery (116, 117).
Breathing
In vitro studies showed that cultivated type II pneumocytes 
express AVP receptor-2 and secrete phospholipoproteins after 
AVP binding, the constituents of surfactant (118, 119). Pulmonary 
surfactant is a surface-active phospholipoprotein complex, is pro-
duced by type II pneumocytes, and acts at the air–water interface 
of alveoli to reduce surface tension. Primary surfactant deficiency 
is a key feature in the pathogenesis of neonatal respiratory distress 
syndrome (RDS). Of interest, a pilot trial in extremely preterm 
infants to evaluate AVP versus dopamine as initial therapy in 
hypotension during the first 24  h of life showed that the AVP 
group received significantly fewer doses of surfactant and had 
lower PaCO2 values than the dopamine group (120). Compared 
to vaginal delivery, infants delivered by cesarean section have a 
significantly increased risk of neonatal admission because of res-
piratory complications mainly due to delayed lung fluid reabsorp-
tion after birth, namely wet lung (121). AVP has been shown to 
decrease the production of fetal lung liquid in ovine fetuses (122), 
and it has been shown that AVP is involved in liquid removal 
from the lungs at birth (123–125). Thus, it might be speculated 
that, in the absence of preconditioning, when primary cesarean 
section was performed, AVP administration shortly after birth to 
the baby, e.g., via nasal spray, might represent a novel strategy to 
support postnatal adaptation.
Analgesia
Peripheral analgesia has been observed in vaginally delivered 
infants on the first day of life and has been linked to AVP 
signaling (4). In particular, animal studies have shown that the 
vasopressin-1A receptor mediates oxytocin and AVP-induced 
analgesia (126, 127).
Cardiovascular System
Apart from water reabsorption in the kidney, vasoconstriction is 
a key function of AVP and has been reviewed elsewhere (128). 
Vasoconstriction is of vital importance to the neonate imme-
diately after delivery to maintain blood pressure by increasing 
peripheral resistance and to close the umbilical cord blood 
vessels. AVP induces a redistribution of fetal blood flow from 
peripheral areas to vital organs (129). On a molar basis, AVP is 
even more potent than norepinephrine and angiotensin II (130). 
In contrast to the peripheral arterioles, AVP reduces pulmonary 
artery resistance through the stimulation of V1 receptors, which 
induces the release of the very potent vasodilator endothelial-
derived nitric oxide (131). This opposing effect of AVP on the 
FiGURe 2 | effects of AvP/ADH on various systems in the healthy and impaired newborn.
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vascular bed is particularly advantageous in the transition from 
placenta to lung breathing and makes AVP a highly attractive 
drug in neonatology (120).
Hemostasis
Arginine vasopressin stimulates the release of coagulation factor, 
von Willebrand factor (VWF), and tissue plasminogen activator 
(t-PA) via V2 receptors on endothelial cells and platelets. AVP 
constitutes an important factor in prothrombotic activity, and the 
AVP analog desmopressin (DDAVP) is widely used in a variety 
of bleeding diseases (132). Interestingly, thrombotic sealing is a 
crucial event for the closure of the ductus arteriosus, promoting 
vascular obliteration and subsequent remodeling (133). Apart 
from the absolute platelet count, platelet function may also play an 
important role in the pathobiology of the ductus arteriosus (134). 
Based on this finding, we speculate that AVP released at birth 
may contribute to the thrombotic sealing of the ductus arteriosus.
Sex Difference
Both in healthy adults as well as in healthy neonates, AVP/
copeptin plasma values are higher in males than in females 
(1, 90, 135–139).
AvP iN NewBORN DiSeASeS
When birth stress is increased because the fetus is compromised 
by prolonged hypoxic events, perinatal hypoxia ischemia 
(asphyxia) may result in which the highest fetal AVP and copep-
tin concentrations have been measured (87, 94, 95). While the 
difference between copeptin concentrations at birth of healthy 
neonates after elective cesarean delivery and vaginal delivery 
is about 100-fold (Figure  1), the difference between healthy 
vaginally delivered neonates and neonates with asphyxia is small 
(only twofold on average) (87). A major complication of asphyxia 
is brain edema, which may lead to increased intracranial pres-
sure and is associated with poor outcome (140). The blood–brain 
barrier (BBB) Na/H exchanger is stimulated by brief exposure to 
hypoxia, aglycemia, and AVP (141) involving the V1 receptor, 
which is present in brain microvessels (142–144). Brain edema in 
animal models could be reduced by an AVP blocker (Conivaptan) 
(145, 146) and aggravated by AVP delivery (147, 148). Moreover, 
in the AVP-deficient Brattleboro rat, brain edema was attenuated 
compared to the control Long–Evans strain (149). Importantly, 
either intranasal AVP or AVP receptor antagonist did not evoke 
edema in the non-ischemic cortex of Mongolian gerbils (148). 
This result could indicate that increased AVP concentrations 
alone, namely after normal vaginal delivery, are insufficient 
to deteriorate the integrity of the BBB and that a severe lack of 
oxygen must be present as well.
A second sequela of asphyxia is the syndrome of inappropriate 
ADH secretion (SIADH), which is also a consequence of exceed-
ingly high levels of AVP/ADH, renal failure, or both (150–154). 
Again, increased AVP concentrations alone, namely after normal 
vaginal delivery, have never been shown to cause SIADH, but they 
cause delayed voiding as described above.
Syndrome of inappropriate ADH secretion is also known as a 
complication of neonatal sepsis. In fact, sudden hyponatremia is a 
typical early sign in the early course of a severe neonatal infection. 
The pro-inflammatory cytokine interleukin-6 directly triggers 
the release of AVP (155, 156).
Chronic stress is associated with chronically elevated AVP/
copeptin levels in rodent as well as human fetuses suffering from 
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intrauterine growth restriction (82, 157, 158). After birth, neo-
nates exposed to chronic stress, such as mechanical respiratory 
support, have elevated plasma copeptin concentrations (159).
AvP iN THeRAPY
Arginine vasopressin and its analogs have not yet been studied 
systematically in neonates (160). Various series of case reports 
indicate that AVP and its analogs are well tolerated and effective in 
neonates as rescue therapy for refractory arterial hypotension and 
particularly for persistent pulmonary hypertension (161–164). 
The recently published results of the first prospective randomized, 
double-blinded, pilot trial comparing AVP and dopamine in the 
treatment of hypotension in extremely low birth weight infants 
demonstrated the safety of AVP in these tiny infants (120). 
Although there were no differences between the two groups con-
cerning time to adequate mean blood pressure, it was shown that 
infants who received vasopressin had lower mean PaCO2 levels 
and needed fewer doses of surfactant than infants who received 
dopamine; additionally, infants who received vasopressin did 
not show tachycardia during drug administration compared to 
infants who received dopamine. The authors believe that these 
effects may be due to the pulmonary vasodilatory effects and lack 
of cardiac effects of vasopressin (120).
CONCLUSiON
In view of the various actions AVP is involved (Figure 2) and the 
close relationship between fetal AVP and arterial pO2, we would 
like to conclude that the surge in fetal stress hormones prior to 
vaginal delivery is the beneficial result of intermittent hypoxic 
preconditioning of the fetus due to the uterine contractions 
required to dilate the cervix and to push the fetus through the 
birth canal.
In respect to diagnostic implications and the data presented 
here (Figure 1), copeptin is apparently the most sensitive birth 
stress biomarker when measured with a clinically established 
assay. Future research will investigate copeptin in the diagnosis 
of AVP-dependent disorders of fluid homeostasis in infants and 
children as well, including nephrogenic and cerebral reasons such 
as increased intracerebral pressure after intraventricular hemor-
rhage, stroke, or traumatic brain injury. Given the sensitivity of 
copeptin to brief hypoxic episodes in animal models, copeptin 
might also be of diagnostic value in unclear clinical situations 
such as apneas or apparent life threatening events.
Together, the availability of quantitative copeptin measure-
ments opens new avenues to study copeptin as an adjunct in the 
diagnosis of various diseases and to further understand AVP 
action.
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